SCHEMBL6336969

SCHEMBL6336969

CCC(Nc1ccc(N(C)C(=O)CCN)cc1)=C1C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.42
PDPK1 O15530 1/20 0.36
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
AHR P35869 1/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
BRD4 O60885 2/20 0.35
BRD2 P25440 1/20 0.35
MTNR1A P48039 3/20 0.34
MTNR1B P49286 3/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
EGFR P00533 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6336960 1.00 RET (0.42) RETPDPK1NPC1POLBAHR
SCHEMBL7476914 1.00 RET (0.42) RETPDPK1NPC1POLBAHR
SCHEMBL6330620 0.94 RET (0.42) RETPDPK1NPC1POLBAHR
SCHEMBL6330607 0.94 RET (0.42) RETPDPK1NPC1POLBAHR
SCHEMBL6329727 0.90 RET (0.40) RETPDPK1NPC1POLBAHR
SCHEMBL6329708 0.90 RET (0.40) RETPDPK1NPC1POLBAHR
SCHEMBL6331077 0.89 RET (0.41) RETNPC1POLBAHRMAPT
SCHEMBL6331068 0.89 RET (0.41) RETNPC1POLBAHRMAPT
SCHEMBL6330824 0.89 RET (0.41) RETPDPK1NPC1POLBAHR
SCHEMBL6330815 0.89 RET (0.41) RETPDPK1NPC1POLBAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885PDPK1 166/4885NPC1 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.